{"disease":{"id":"neuroblastoma","name":"Neuroblastoma","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":20,"pipeline_drug_count":0,"trial_count":30},"drugs":{"marketed":[{"drug_id":"nivestym","indication_name":"Enhancement of an antitumor effect of dinutuximab for neuroblastoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Neupogen","generic_name":"Filgrastim-Aafi","company_name":"Amgen","drug_phase":"marketed","molecular_target":"G-CSF receptor (granulocyte colony-stimulating factor receptor)","drug_class":"Colony-stimulating factor (CSF); leukocyte growth factor","quality_score":10,"revenue":"1434.0","mechanism":"Filgrastim-aafi binds G-CSF receptors on hematopoietic cells, stimulating neutrophil proliferation, differentiation, and functional activation."},{"drug_id":"cyclophosphamide","indication_name":"Neuroblastoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytoxan (Lyophilized)","generic_name":"cyclophosphamide","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Tumor cell DNA","drug_class":"Alkylating agent","quality_score":10,"revenue":"1000.0","mechanism":"Cyclophosphamide cross-links tumor cell DNA and interferes with malignant cell growth through active alkylating metabolites."},{"drug_id":"chembl-chembl359744","indication_name":"Metastatic Neuroblastoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DOXORUBICIN HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"topoisomerase II","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Doxorubicin works by intercalating DNA, inhibiting nucleotide replication, and forming DNA-cleavable complexes with topoisomerase II."},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic neuroblastoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"oncovin","indication_name":"Neuroblastoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Oncovin","company_name":"University of Colorado, Denver","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 7, Multidrug resistance protein 1","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"vincristin","indication_name":"Neuroblastoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Vincristin","company_name":"Arbeitsgemeinschaft medikamentoese Tumortherapie","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 7, Multidrug resistance protein 1","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"neupogen","indication_name":"Enhancement of an antitumor effect of dinutuximab for neuroblastoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Neupogen","company_name":"University of Chicago","drug_phase":"marketed","molecular_target":"Granulocyte colony-stimulating factor receptor","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"doxorubicin-hydrochloride","indication_name":"Metastatic neuroblastoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Doxorubicin Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"DNA topoisomerase II, nucleotide bases","drug_class":"Anthracycline topoisomerase inhibitor","quality_score":70,"revenue":null,"mechanism":"Doxorubicin intercalates nucleotide bases and interacts with topoisomerase II to form DNA-cleavable complexes, inhibiting DNA/RNA replication."},{"drug_id":"adriacin","indication_name":"Neuroblastoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"adriacin","company_name":"Chipscreen Biosciences, Ltd.","drug_phase":"phase_1","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"hydroxydaunorubicin","indication_name":"Neuroblastoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxydaunorubicin","company_name":"University of Colorado, Denver","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"cyclophosphamid","indication_name":"Neuroblastoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cyclophosphamid","company_name":"Zhejiang University","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"naxitamab-gqgk","indication_name":"Neuroblastoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"DANYELZA","generic_name":"NAXITAMAB-GQGK","company_name":"Y-MABS THERAPEUTICS INC","drug_phase":"marketed","molecular_target":"GD2","drug_class":"Glycolipid Disialoganglioside-directed Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":"Naxitamab-gqgk binds to GD2 on neuroblastoma cells, inducing CDC and ADCC."},{"drug_id":"busilvex","indication_name":"Neuroblastoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Busilvex","company_name":"medac GmbH","drug_phase":"phase_2","molecular_target":"Matrix metalloproteinase-9","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"naxitamab","indication_name":"Neuroblastoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hu3F8","generic_name":"NAXITAMAB","company_name":"Y-Mabs Therapeutics Inc","drug_phase":"marketed","molecular_target":"","drug_class":"Glycolipid Disialoganglioside-directed Antibody [EPC]","quality_score":53,"revenue":null,"mechanism":"Hu3F8 works by binding to a specific glycolipid on cancer cells, marking them for destruction by the immune system."},{"drug_id":"vincristine-sulfate-pfs","indication_name":"Neuroblastoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Oncovin","generic_name":"Vincristine Sulfate","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1","drug_class":"Vinca Alkaloid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"vincristine","indication_name":"Neuroblastoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Oncovin","generic_name":"vincristine","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1","drug_class":"Vinca Alkaloid","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"liposomal-doxorubicin","indication_name":"Neuroblastoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Liposomal Doxorubicin","generic_name":"liposomal-doxorubicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase","drug_class":"doxorubicin","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"busulfan","indication_name":"Neuroblastoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Busulfex","generic_name":"busulfan","company_name":"Waylis","drug_phase":"marketed","molecular_target":"Matrix metalloproteinase-9","drug_class":"Alkylating Drug [EPC]","quality_score":10,"revenue":null,"mechanism":"Busulfex works by attaching an alkyl group to the DNA of cancer cells, interfering with their ability to replicate and ultimately leading to cell death."},{"drug_id":"doxorubicin","indication_name":"Neuroblastoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Doxorubicin Hydrochloride","generic_name":"doxorubicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aurora kinase A","drug_class":"Anthracycline Topoisomerase Inhibitor","quality_score":80,"revenue":null,"mechanism":"Doxorubicin works by intercalating DNA strands and inhibiting topoisomerase II, an enzyme essential for DNA replication and cell division."},{"drug_id":"chembl-chembl1200796","indication_name":"Neuroblastoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytoxan (Lyophilized)","generic_name":"CYCLOPHOSPHAMIDE","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"cyclophosphamide","quality_score":10,"revenue":null,"mechanism":"Cytoxan works by interfering with the DNA replication process in rapidly dividing cancer cells."},{"drug_id":"dinutuximab","indication_name":"Neuroblastoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ch14.18","generic_name":"DINUTUXIMAB","company_name":"United Therap","drug_phase":"marketed","molecular_target":"GD2","drug_class":"Glycolipid Disialoganglioside-directed Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":"Dinutuximab binds to GD2 on neuroblastoma cells and induces cell lysis via ADCC and CDC."},{"drug_id":"hydroxydaunomycin","indication_name":"Neuroblastoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxydaunomycin","company_name":"Weill Medical College of Cornell University","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"adriamycin","indication_name":"Neuroblastoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Adriamycin","company_name":"Johann Wolfgang Goethe University Hospital","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"busulfex","indication_name":"Neuroblastoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"busulfex","company_name":"Dana-Farber Cancer Institute","drug_phase":"marketed","molecular_target":"Matrix metalloproteinase-9","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"vincristine-sulfate-pfs","indication_name":"Neuroblastoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Oncovin","generic_name":"Vincristine Sulfate","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1","drug_class":"Vinca Alkaloid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"busulphan","indication_name":"Neuroblastoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Busulphan","company_name":"University of Birmingham","drug_phase":"discontinued","molecular_target":"Matrix metalloproteinase-9","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"naxitamab","indication_name":"Relapsed or Refractory High-Risk Neuroblastoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hu3F8","generic_name":"NAXITAMAB","company_name":"Y-Mabs Therapeutics Inc","drug_phase":"marketed","molecular_target":"","drug_class":"Glycolipid Disialoganglioside-directed Antibody [EPC]","quality_score":53,"revenue":null,"mechanism":"Hu3F8 works by binding to a specific glycolipid on cancer cells, marking them for destruction by the immune system."}],"pipeline":[],"offLabel":[],"totalMarketed":27,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00904241","title":"Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT00436696","title":"Genetic Analysis Using Blood or Bone Marrow From Participants With Neuroblastoma or Noncancerous Conditions","phase":"","overall_status":"COMPLETED","enrollment_count":9350,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT07072143","title":"An International Study on Pediatric Patients With Rare Tumors.","phase":"","overall_status":"RECRUITING","enrollment_count":6250,"lead_sponsor_name":"Azienda Ospedaliera di Padova","has_results":false},{"nct_id":"NCT01109394","title":"Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies","phase":"","overall_status":"RECRUITING","enrollment_count":6035,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03382158","title":"International PPB/DICER1 Registry","phase":"","overall_status":"RECRUITING","enrollment_count":3400,"lead_sponsor_name":"Children's Hospitals and Clinics of Minnesota","has_results":false},{"nct_id":"NCT01005654","title":"Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms","phase":"","overall_status":"RECRUITING","enrollment_count":2415,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06822842","title":"Accurate Diagnosis and Grading of Pediatric Solid Tumors Based on Pathological Large Models","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT00026780","title":"Eligibility Screening for a NCI Pediatric Oncology Branch Research Study","phase":"","overall_status":"COMPLETED","enrollment_count":1720,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03050268","title":"Familial Investigations of Childhood Cancer Predisposition","phase":"","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":false},{"nct_id":"NCT00026312","title":"Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1449,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03155620","title":"Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1377,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03583528","title":"DOTATOC PET/CT for Imaging NET Patients","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":800,"lead_sponsor_name":"British Columbia Cancer Agency","has_results":false},{"nct_id":"NCT03126916","title":"Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":750,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT01728155","title":"European Low and Intermediate Risk Neuroblastoma Protocol","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":685,"lead_sponsor_name":"Instituto de Investigacion Sanitaria La Fe","has_results":false},{"nct_id":"NCT00567567","title":"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":665,"lead_sponsor_name":"Children's Oncology Group","has_results":true},{"nct_id":"NCT02176967","title":"Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":621,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT03496402","title":"Biological Characterisation of High Risk CHildhood Cancer in Children, Adolescents and Young Adults (MICCHADO)","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":600,"lead_sponsor_name":"Institut Curie","has_results":false},{"nct_id":"NCT05192980","title":"SIOPEN BIOPORTAL, An International Registry Linked to a Virtual Biobank for Patients With Peripheral Neuroblastic Tumours","phase":"NA","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Institut Curie","has_results":false},{"nct_id":"NCT01119560","title":"Genetic Susceptibility Biomarkers in Children With Neuroblastoma (Also Known as Neuroblastoma Epidemiology in North America [NENA])","phase":"","overall_status":"COMPLETED","enrollment_count":576,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT04755205","title":"A Natural History Study of Children and Adults With Olfactory Neuroblastoma","phase":"","overall_status":"RECRUITING","enrollment_count":525,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT00840047","title":"Methionine PET/CT Studies In Patients With Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":503,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":false},{"nct_id":"NCT06703944","title":"Risk Model for Metastasis Detection of Neuroblastoma","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":500,"lead_sponsor_name":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT06172296","title":"Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":478,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT00499616","title":"Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":464,"lead_sponsor_name":"Children's Oncology Group","has_results":true},{"nct_id":"NCT05179850","title":"Computer Aided Diagnostic Tool on Computed Tomography Images for Diagnosis of Retroperitoneal Tumor in Children","phase":"","overall_status":"UNKNOWN","enrollment_count":400,"lead_sponsor_name":"West China Hospital","has_results":false},{"nct_id":"NCT04087902","title":"Long-Term Longitudinal QoL in Patients Undergoing EEA","phase":"","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Ohio State University","has_results":false},{"nct_id":"NCT03042416","title":"18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":400,"lead_sponsor_name":"University of Alberta","has_results":false},{"nct_id":"NCT03057626","title":"Late Effects After Treatment in Patients With Previously Diagnosed High-Risk Neuroblastoma","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":376,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT06873672","title":"Validation of the EQ-5D-Y-3L and EQ-5D-Y-5L for Paediatric Patients in China","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":360,"lead_sponsor_name":"RenJi Hospital","has_results":false},{"nct_id":"NCT03042429","title":"Combination Chemotherapy Followed by Stem Cell Transplant in High-risk Neuroblastoma Patients","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":360,"lead_sponsor_name":"University of Cologne","has_results":false},{"nct_id":"NCT02177773","title":"GA-68 DOTA-TOC of Somatostatin Positive Malignancies","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":300,"lead_sponsor_name":"University of California, San Francisco","has_results":true},{"nct_id":"NCT04936529","title":"A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":286,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT00126412","title":"Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":251,"lead_sponsor_name":"GE Healthcare","has_results":false},{"nct_id":"NCT04474678","title":"Quality Improvement Project - \"My Logbook! - I Know my Way Around!\"; (\"Mein Logbuch - Ich Kenne Mich Aus!\")","phase":"NA","overall_status":"COMPLETED","enrollment_count":240,"lead_sponsor_name":"Medical University of Vienna","has_results":false},{"nct_id":"NCT01619865","title":"Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":223,"lead_sponsor_name":"Sue O'Dorisio","has_results":true},{"nct_id":"NCT00898755","title":"Collecting and Storing Tissue From Young Patients With Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":213,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT04081701","title":"68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Weill Medical College of Cornell University","has_results":false},{"nct_id":"NCT06296732","title":"Abdominal Neuroblastoma Laparoscopic Surgery Risk Factors Stratification","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","has_results":false},{"nct_id":"NCT07516678","title":"Serial ctDNA and Molecular Residual Disease Monitoring in Neuroblastoma","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT02162732","title":"Molecular-Guided Therapy for Childhood Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":186,"lead_sponsor_name":"Giselle Sholler","has_results":true},{"nct_id":"NCT00089245","title":"Radiolabeled MAB Therapy in Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":177,"lead_sponsor_name":"Y-mAbs Therapeutics","has_results":false},{"nct_id":"NCT00536601","title":"High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors","phase":"NA","overall_status":"COMPLETED","enrollment_count":174,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT07334301","title":"A Multi-Arm, Platform Trial For Relapsed Neuroblastoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":160,"lead_sponsor_name":"University of Birmingham","has_results":false},{"nct_id":"NCT01857934","title":"Therapy for Children With Advanced Stage Neuroblastoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":153,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":true},{"nct_id":"NCT01798004","title":"Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Children's Oncology Group","has_results":true},{"nct_id":"NCT07064746","title":"Clinical Application Study of [123I]Metaiodobenzylguanidine and Somatostatin Receptor-Targeted Imaging in the Diagnosis and Staging of Neuroblastoma","phase":"","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Nanjing First Hospital, Nanjing Medical University","has_results":false},{"nct_id":"NCT04851119","title":"Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":147,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT03236857","title":"A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":143,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT02304458","title":"Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":140,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02395666","title":"Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":140,"lead_sponsor_name":"Giselle Sholler","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}